Drug intelligence / Profile preview

YM3711

Development stage: Preclinical
Lead developer: VITRUVIAN BioMedical
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

YM3711 is a gene-based DNA vaccine developed by Vitruvian BioMedical for the treatment of Alzheimer's Disease. It specifically targets amyloid-beta (ABeta) peptides, aiming to induce an immune response that reduces the accumulation of ABeta plaques in the brain. Unlike the company's lead candidate YM7555, which targets both ABeta and TAU, YM3711 is a monovalent vaccine focused solely on ABeta. The drug is currently in the IND-enabling stage, preparing for clinical trials.

Other names: YM3711 DNA vaccineYM-3711 DNA vaccineYM 3711 DNA vaccineVitruvian ABeta DNA vaccine

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on YM3711.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YM3711.

Explore the full profile